Molecular biology, genomics, and proteomics in bronchioloalveolar carcinoma.
The charge of the Molecular Biology, Genomics, and Proteomics in Bronchioloalveolar Carcinoma Committee was to evaluate the molecular biology, genomic changes, and proteomic findings in patients with bronchioloalveolar carcinoma compared with other types of lung cancer. The literature was reviewed and unpublished information was presented by the committee members at the session. The molecular biology studies have included findings on epidermal growth factor receptor (EGFR) mutations, p53 mutations, K-ras mutations, and loss of heterozygosity. The genomic changes have mostly focused on the mRNA expression arrays as well as protein studies. The current state of knowledge was reviewed, the missing information was acknowledged, and proposals for future research were identified.
Wislez
Marie
M
Service de Pneumologie et de Réanimation Respiratoire, AP-HP, Hôpital Tenon and Laboratoire de Biologie Cellulaire et d'Immunopathologie Pulmonaire, Université Paris VI, Paris, France.
Beer
David G
DG
Wistuba
Ignacio
I
Cadranel
Jacques
J
Saijo
Nagahiro
N
Johnson
Bruce E
BE
D000230:Adenocarcinoma / Q000235:genetics / Q000473:pathology; D002282:Adenocarcinoma, Bronchiolo-Alveolar / Q000235:genetics* / Q000473:pathology; D001707:Biopsy, Needle; D004252:DNA Mutational Analysis; D004273:DNA, Neoplasm / Q000032:analysis; D066246:ErbB Receptors / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D020022:Genetic Predisposition to Disease; D023281:Genomics / Q000379:methods*; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000235:genetics* / Q000473:pathology; D008967:Molecular Biology; D009367:Neoplasm Staging; D011379:Prognosis; D040901:Proteomics / Q000379:methods; D012680:Sensitivity and Specificity
D004273:DNA, Neoplasm; D066246:ErbB Receptors